Q3 EPS Forecast for Oruka Therapeutics Decreased by Analyst

Key Points

• HC Wainwright has reduced its Q3 2025 earnings estimate for Oruka Therapeutics to ($0.54) per share, slightly down from the previous estimate of ($0.53).
• The consensus estimate for Oruka Therapeutics' FY2025 earnings is ($2.23) per share, while the company recently reported quarterly earnings of ($0.46) EPS, beating the consensus estimate of ($0.48) by $0.02.
• Oruka Therapeutics currently holds a Buy rating from HC Wainwright with a target price of $45.00, while institutional investors own about 56.44% of the company’s stock.

Oruka Therapeutics, Inc. (NASDAQ:ORKA - Free Report) - Equities research analysts at HC Wainwright dropped their Q3 2025 earnings estimates for Oruka Therapeutics in a research report issued on Monday, August 18th. HC Wainwright analyst M. Kapoor now forecasts that the company will post earnings of ($0.54) per share for the quarter, down from their prior estimate of ($0.53). HC Wainwright currently has a "Buy" rating and a $45.00 price target on the stock. The consensus estimate for Oruka Therapeutics' current full-year earnings is ($3.41) per share. HC Wainwright also issued estimates for Oruka Therapeutics' FY2025 earnings at ($2.23) EPS, Q2 2026 earnings at ($0.68) EPS and FY2026 earnings at ($2.77) EPS.

A number of other research analysts also recently commented on the company. Wall Street Zen downgraded Oruka Therapeutics from a "hold" rating to a "sell" rating in a research note on Saturday, August 16th. Wedbush reaffirmed an "outperform" rating and issued a $40.00 price objective on shares of Oruka Therapeutics in a report on Tuesday, August 12th. Finally, BTIG Research assumed coverage on shares of Oruka Therapeutics in a research report on Thursday, May 22nd. They issued a "buy" rating on the stock. Two equities research analysts have rated the stock with a Strong Buy rating and eight have assigned a Buy rating to the company. According to data from MarketBeat.com, Oruka Therapeutics presently has an average rating of "Buy" and a consensus price target of $40.38.

Oruka Therapeutics Price Performance

Shares of NASDAQ ORKA traded up $0.65 during mid-day trading on Wednesday, hitting $15.44. The company had a trading volume of 152,697 shares, compared to its average volume of 142,141. The stock has a market cap of $578.23 million, a price-to-earnings ratio of -5.49 and a beta of -0.35. Oruka Therapeutics has a 12 month low of $5.49 and a 12 month high of $52.32. The firm's 50 day simple moving average is $13.56 and its two-hundred day simple moving average is $11.59.

Oruka Therapeutics (NASDAQ:ORKA - Get Free Report) last issued its quarterly earnings results on Monday, August 11th. The company reported ($0.46) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.48) by $0.02.

Institutional Investors Weigh In On Oruka Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the business. Legal & General Group Plc acquired a new stake in Oruka Therapeutics in the 2nd quarter valued at about $28,000. Ameritas Investment Partners Inc. acquired a new position in shares of Oruka Therapeutics in the 2nd quarter valued at about $31,000. JPMorgan Chase & Co. acquired a new position in shares of Oruka Therapeutics in the 4th quarter valued at about $54,000. BNP Paribas Financial Markets increased its holdings in shares of Oruka Therapeutics by 464.0% in the 2nd quarter. BNP Paribas Financial Markets now owns 2,803 shares of the company's stock valued at $31,000 after purchasing an additional 2,306 shares during the period. Finally, Police & Firemen s Retirement System of New Jersey acquired a new position in shares of Oruka Therapeutics in the 2nd quarter valued at about $68,000. 56.44% of the stock is owned by institutional investors and hedge funds.

About Oruka Therapeutics

Oruka Therapeutics, Inc is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. Its pipeline includes ORKA-001 and ORKA-002. The company is headquartered in Menlo Park, CA.